Abstract:Background: Perineural invasion (PNI) is an important mechanism associated with metastasis in malignancies, including intrahepatic cholangiocarcinoma (ICC), and is correlated with poor prognosis. However, the molecular features and their relationship with the prognosis of ICC patients with PNI remain unclear.Methods: Prognostic implications of PNI were investigated in MSK cohort and was validated in our independent cohort of patients with ICC using the Kaplan–Meier method. PNI-related genomic profiles were analyzed in the MSK cohort, and the PNI-related transcriptomic atlas was examined in the ZS-ICC cohort from our team. GO, KEGG, and ssGSEA analysis were performed. Immunohistochemistry was used to investigate the relationship between PNI and markers of neurons, hydrolases, and immune cells. The efficacy of adjuvant therapy in ICC patients with PNI was also assessed.Findings: A total of 30.6% and 20.7% patients with ICC had PNI in the discovery and validation cohorts respectively. Patients with PNI in both cohorts presented with shortened overall survival (OS) and relapse-free survival (RFS). The PNI showed positive expression of tyrosine hydroxylase (TH), a marker of sympathetic nerves. Patients with PNI showed a high frequency of KRAS mutations, decreased NK cell infiltration, increased neutrophil infiltration, and elevated expression of PD-L1, CD80, and CD86. Patients with PNI benefited from an extended OS after adjuvant therapy with TEGIO, GEMOX, or capecitabine.Interpretation: Our study deciphered the molecular features of a high frequency of KRAS mutation, positive TH expression, increased neutrophil infiltration, and decreased NK cell infiltration in ICC patients with PNI. Patients with PNI showed a poor prognosis after surgery but a good response to adjuvant chemotherapy.Funding Information: This study was supported by the Clinical Research Plan of SHDC (SHDC 2020CR1003A), the Key Disease Joint Research Program of Xuhui District (XHLHGG202103), the National Key Research and Development Program of China (2019YFC1316000), the National Natural Science Foundation of China (81972232), the Clinical Medicine Research Pilot Project of Shanghai Medical School of Fudan University, the Shanghai Municipal Natural Science Foundation (20JC1419103), Beijing Mutual Care Public Welfare Foundation (GDXZ-08-05) and Sanming Project of Medicine in Shenzhen (No. SZSM202003009).Declaration of Interests: There is no competing interest between all authors.Ethics Approval Statement: The study was approved by the Institutional Review Board of Zhongshan Hospital (Y2017-130), and all related procedures conformed to the Declaration of Helsinki.

The Role of Purine Metabolism-Related Genes PPAT and IMPDH1 in the Carcinogenesis of Intrahepatic Cholangiocarcinoma Based on Metabonomic and Bioinformatic Analyses

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma

Multi-omics-driven Discovery of Invasive Patterns and Treatment Strategies in CA19-9 Positive Intrahepatic Cholangiocarcinoma

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma

Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma

Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy

Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues

Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma.

Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated with Tumor Recurrence in Patients.

Protein Tyrosine Phosphatase PTP4A1 Promotes Proliferation and Epithelial-Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Via the PI3K/AKT Pathway

PD-1/PD-L1 Expression Profiles Within Intrahepatic Cholangiocarcinoma Predict Clinical Outcome

Intrahepatic Cholangiocarcinoma:Role of Metabolism in Pathogenesis, Clinical Diagnosis,and Treatment

MicroRNA‐191 Acts As a Tumor Promoter by Modulating the TET1–p53 Pathway in Intrahepatic Cholangiocarcinoma

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

The Clinical Implications and Molecular Features of Intrahepatic Cholangiocarcinoma with Perineural Invasion.

Low Expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated with Cold Tumor Microenvironment.

Mutational landscape of intrahepatic cholangiocarcinoma